Refine by
Antigen Receptors Equipment Supplied In Belgium
6 equipment items found
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-221 is a preclinical short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. CYAD-221 is engineered to co-express a CD19 chimeric antigen receptor and an shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology ...
Manufactured by:SYnAbs S.A. based inGosselies, BELGIUM
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very difficult to access due to intrinsic properties. ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...